{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-036818","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.063214+00:00","generated_at":"2026-05-15T08:21:35.821930+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Fortress Biotech subsidiary Cyprium closes PRV sale for $205M; Fortress expects over $100M","bullets":["Cyprium sold Rare Pediatric Disease Priority Review Voucher for $205M gross proceeds.","Fortress (80.4% owner) expects over $100M from dividends and intercompany agreements.","PRV was issued upon FDA approval of ZYCUBO (copper histidinate) on Jan 12, 2026.","Cyprium redeemed all outstanding 9.375% Perpetual Preferred Stock in connection with sale.","Cyprium remains eligible for tiered royalties on ZYCUBO sales and up to ~$128M in milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-036818","json":"https://secwatch.observer/filing/0001104659-26-036818.json","markdown":"https://secwatch.observer/filing/0001104659-26-036818.md","text":"https://secwatch.observer/filing/0001104659-26-036818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000110465926036818/0001104659-26-036818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000110465926036818/fbio-20260330x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:21:35.821930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}